How we approach an acquired thrombotic thrombocytopenic purpura patient

Transfusion

Volumn 54, Issue 10, 2014, Pages 2375-2382

  Raval, Jay S ^a   Mazepa, Marshall A ^a   Brecher, Mark E ^a,b   Park, Yara A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA; ARTICLE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMA VOLUME; PLASMAPHERESIS; THERAPEUTIC PLASMA EXCHANGE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; ALGORITHM; APHERESIS; GENETIC SCREENING; GENETICS; MULTIMODALITY CANCER THERAPY; PATIENT REFERRAL; PROCEDURES; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

ADAM PROTEINS; ALGORITHMS; BLOOD COMPONENT REMOVAL; COMBINED MODALITY THERAPY; GENETIC TESTING; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REFERRAL AND CONSULTATION;

EID: 84908116395     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12794     Document Type: Article

References (50)

1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
2. Bandarenko N, Brecher ME,. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher 1998; 13: 133-141.
3. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
4. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
5. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435.
6. Cohen JA, Brecher ME, Bandarenko N,. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13: 16-19.
7. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29: 148-167.
8. Booth KK, Terrell DR, Vesely SK, et al. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86: 743-751.
9. Zini G, d'Onofrio G, Briggs C, et al.; International Council for Standardization in H. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol 2012; 34: 107-116.
10. Benhamou Y, Assie C, Boelle PY, et al.; Thrombotic Microangiopathies Reference Center. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 2012; 97: 1181-1186.
11. Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 2009; 7: 529-536.
12. Nichols L, Berg A, Rollins-Raval MA, et al. Cardiac injury is a common postmortem finding identified in autopsied thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed? Ther Apher Dial 2014. doi: 10.1111/1744-9987.12191.
13. Park YA, Hay SN, King KE, et al. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. J Clin Apher 2009; 24: 115-119.
14. Egan JA, Bandarenko N, Hay SN, et al. Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. J Clin Apher 2004; 19: 125-129.
15. Brecher ME, Hay SN, Park YA,. Is it HIV TTP or HIV-associated thrombotic microangiopathy? J Clin Apher 2008; 23: 186-190.
16. Coppo P, Schwarzinger M, Buffet M, et al.; French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center experience. PloS One 2010; 5: e10208.
17. Cataland SR, Holers VM, Geyer S, et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014; 123: 3733-3738.
18. Creager AJ, Brecher ME, Bandarenko N,. Thrombotic thrombocytopenic purpura that is refractory to therapeutic plasma exchange in two patients with occult infection. Transfusion 1998; 38: 419-423.
19. Park YA, Schultz EF, Hay SN, et al. Thrombotic thrombocytopenic purpura and urinary tract infections: is there a connection? Am J Clin Pathol 2011; 135: 85-88.
20. Hay SN, Egan JA, Millward PA, et al. Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state. Ther Apher Dial 2006; 10: 237-241.
21. Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28: 145-284.
22. Scully M, Hunt BJ, Benjamin S, et al.; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323-335.
23. Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 2008; 48: 349-357.
24. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511. quiz 662.
25. Egan JA, Hay SN, Brecher ME,. Frequency and significance of schistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy. J Clin Apher 2004; 19: 165-167.
26. Zhan H, Streiff MB, King KE, et al. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion 2010; 50: 868-874.
27. Scott EA, Puca KE, Pietz BC, et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007; 47: 120-125.
28. Brecher ME, Hay SN, Park YA,. Theoretical efficacy of using albumin/plasma versus full plasma replacement in TTP. J Clin Apher 2011; 26: 58.
29. O'Brien KL, Price TH, Howell C, et al. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura. J Clin Apher 2013; 28: 416-420.
30. Reutter JC, Sanders KF, Brecher ME, et al. Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001; 16: 134-138.
31. Winters JL,. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program 2012; 2012: 7-12.
32. McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-1208.
33. Stigelman WH, Jr, Henry DH, Talbert RL, et al. Removal of prednisone and prednisolone by plasma exchange. Clin Pharm 1984; 3: 402-407.
34. Caramazza D, Quintini G, Abbene I, et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010; 50: 2753-2760.
35. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
36. Pasquale D, Vidhya R, DaSilva K, et al. Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. Am J Hematol 1998; 57: 57-61.
37. Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005; 45: 41-49.
38. Beloncle F, Buffet M, Coindre JP, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 2012; 52: 2436-2444.
39. Allan DS, Kovacs MJ, Clark WF,. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001; 86: 844-850.
40. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 146-149.
41. US National Institutes of Health. ClinicalTrials.gov. [cited 2014 Jul 9]. Available from: https://clinicaltrials.gov/ct2/results?term=%22thrombotic+thrombocytopenic+purpura%22&recr=Open.
42. Millward PM, Bandarenko N, Chang PP, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion 2005; 45: 1481-1486.
43. Mazepa MA, Raval JS, Moll S, et al. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2014; 164: 900-902.
44. Chapin J, Weksler B, Magro C, et al. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012; 157: 772-774.
45. Tsai E, Chapin J, Laurence JC, et al. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol 2013; 162: 558-559.
46. Wu TC, Yang S, Haven S, et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1925-1927.
47. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662-666.
48. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009; 41: 105-107.
49. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
50. Shortt J, Oh DH, Opat SS,. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368: 90-92.